Literature DB >> 3090477

Immunobiology of brain tumors.

E Frank, N de Tribolet.   

Abstract

The treatment of the cerebral glioma continues to challenge neurosurgeons and basic scientists. The lack of major success with chemotherapy and radiation therapy has spurred further investigation into the biology of this tumor and host reactions to it. Much of this research has centred upon evaluation of tumor cell antigenicity and the cellular immune responses to the glioma. Contrary to previous considerations evidence suggests that astrocytes, glioma cells and tumor endothelial cells may all have pivotal roles in the initiation and prolongation of both local and systemic immune responses to the tumor. In this review we will discuss the immunobiology of the glioma with specific reference to the interactions between the tumor and the host immune system. In addition, ideas for potential therapeutic manipulation of the host-glioma immune interactions will be reviewed stressing potential pitfalls and risks.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090477     DOI: 10.1007/bf01743051

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  38 in total

Review 1.  The immunobiology of human gliomas.

Authors:  V Piguet; A C Diserens; S Carrel; J P Mach; N de Tribolet
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Antigen presentation: comments on its regulation and mechanism.

Authors:  E R Unanue; D I Beller; C Y Lu; P M Allen
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

Review 3.  Monoclonal antibodies as reagents for brain tumour diagnosis: a review.

Authors:  H B Coakham; J A Garson; B Brownell; J T Kemshead
Journal:  J R Soc Med       Date:  1984-09       Impact factor: 5.344

4.  Letter: Impaired cell-mediated immunity in human brain tumours.

Authors:  D G Thomas; C B Lannigan; P O Behan
Journal:  Lancet       Date:  1975-06-21       Impact factor: 79.321

5.  Therapeutic potential for blood-brain barrier modification in malignant brain tumor.

Authors:  E A Neuwelt
Journal:  Prog Exp Tumor Res       Date:  1984

6.  Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.

Authors:  S Carrel; N De Tribolet; N Gross
Journal:  Eur J Immunol       Date:  1982-04       Impact factor: 5.532

7.  Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies.

Authors:  R C Seeger; H M Rosenblatt; K Imai; S Ferrone
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

8.  Hybrid myelomas producing antibodies against a human neuroblastoma antigen present on fetal brain.

Authors:  R H Kennett; F Gilbert
Journal:  Science       Date:  1979-03-16       Impact factor: 47.728

9.  In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.

Authors:  M K Gately; M Glaser; S J Dick; R W Mettetal; P L Kornblith
Journal:  J Natl Cancer Inst       Date:  1982-12       Impact factor: 13.506

10.  Immunohistological diagnosis of central nervous system tumours using a monoclonal antibody panel.

Authors:  H B Coakham; J A Garson; P M Allan; E I Harper; B Brownell; J T Kemshead; E B Lane
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

View more
  2 in total

1.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

2.  The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study.

Authors:  K R von Wild; T H Knocke
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.